论文部分内容阅读
通过查阅29篇文献,对黄蜀葵花的成分、现代临床与药效、体内过程、相关知识产权专利进行归纳总结;该植物所含成分主要为以杨梅素、槲皮素、棉皮素为母核的黄酮类化合物;用于慢性肾脏病、感染创面,具有抑制免疫、抗炎作用;其在体内的代谢过程,以羧基化反应、乙酰化反应、水解反应为主,被动扩散吸收;相关知识产权集中在成分提取、制备工艺、药物配伍方面,涉及疾病集中于慢性肾病方面。现代临床与基础研究对黄蜀葵花的研究与挖掘明显不足。扩大黄蜀葵花适应症,深化基础与临床研究,具有良好前景。本文综述黄蜀葵花近10年来的研究进展,以期为其进一步研究开发提供参考。
Through reviewing 29 literatures, the author summarizes the composition, modern clinical and pharmacological effects, in vivo processes and patents of related intellectual property of the flower of Abelmoschus. The plant contains mainly myricetin, quercetin and naringin as mother nuclei Of flavonoids; for chronic kidney disease, wound infection, with immune suppression, anti-inflammatory effect; its metabolic process in vivo, mainly to carboxylation, acetylation, hydrolysis reaction, passive diffusion absorption; related intellectual property Focus on the extraction of ingredients, preparation techniques, drug compatibility, involving the disease focused on chronic kidney disease. Modern clinical and basic research on Abelia flower research and excavation is obviously inadequate. Expand Abacus indications, deepen the basic and clinical research, with good prospects. This review summarizes the research progress of Abelmoschus manihot in the past 10 years, in order to provide reference for further research and development.